Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ciro Roberto Rinaldi"'
Autor:
Alfredo Addeo, Ciro Roberto Rinaldi
Publikováno v:
Case Reports in Oncology, Vol 6, Iss 2, Pp 285-288 (2013)
Introduction: Over the past year, 3 agents have been approved for the treatment of melanoma by the Food and Drug Administration. These include pegylated interferon α-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with
Externí odkaz:
https://doaj.org/article/11309585d2e84233af00513cafa3768a
Publikováno v:
Case Reports in Hematology, Vol 2013 (2013)
The allogeneic bone marrow transplantation usually preceded by induction chemotherapy, in fit patients, represents the gold standard in the acute myeloid leukaemia. In the last years, many trials have been set up with the view of improving the number
Externí odkaz:
https://doaj.org/article/4491b02fe6b840349457081333422db8
Autor:
James Lally, Christian Marinaccio, Lilia Brown, Vincenzo Martinelli, Vishaka Sovani, Ciro Roberto Rinaldi, Ciaren Graham, Kristian Boasman, John D. Crispino, Ilaria Cappuccio
Publikováno v:
Lally, J, Brown, L, Martinelli, V, Cappuccio, I, Sovani, V, Marinaccio, C, Crispino, J D, Graham, C, Rinaldi, C & Boasman, K 2019, ' GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis ', Journal of Thrombosis and Haemostasis . https://doi.org/10.1111/jth.14433
Essentials The BCR-ABL negative myeloproliferative neoplasms are subjected to unknown phenotypic modifiers. GATA-1 is upregulated in ET patients, regardless of treatment regimen or mutational status. Myelofibrosis (MF) megakaryocytes displayed decrea
Autor:
Ciro Roberto Rinaldi, Yogen Saunthararajah, Matthew J. Simmonds, Ciaren Graham, Kristian Boasman
Publikováno v:
Annals of Hematology. 98:1529-1531
Publikováno v:
Journal of Clinical Oncology. 38:7557-7557
Myelodysplastic neoplasms (MPN) and myelodysplastic syndrome (MDS) are myeloid malignancies characterized by either overproduction of mature blood cells or hyperplastic bone marrow and peripheral cytopenia, but both with a tendency to evolve into acu
Autor:
Bruno Martino, Hui-Ling Zhen, Francesco Passamonti, Pierre Zachee, Ruben A. Mesa, Deborah S. Hunter, Steffen Koschmieder, Ciro Roberto Rinaldi, Mark M. Jones, Yasmin Hasan, Abdulraheem Yacoub, Mamta Garg, Srdan Verstovsek, Alessandro M. Vannucchi, Dany Habr, Jennifer Byrne, Roger M. Lyons
Publikováno v:
British journal of haematology 176(1), 76-85 (2017). doi:10.1111/bjh.14382
British Journal of Haematology
British Journal of Haematology
British journal of haematology 176(1), 76-85 (2017). doi:10.1111/bjh.14382
Published by Wiley-Blackwell, Oxford [u.a.]
Published by Wiley-Blackwell, Oxford [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e854e8aa13c4eea6236c671d85278079
Publikováno v:
Journal of Global Oncology. 5:48-48
48 Background: In solid tumours, calreticulin (CALR) overexpression produces a pro-phagocytic signal and is counteracted by concomitant expression of anti- phagocytic CD47, reflecting an apoptosis vs survival mechanism. Increases of both CALR and CD4
Publikováno v:
Blood. 132:5492-5492
Myeloproliferative neoplasms (MPN) are chronic myeloid cancers characterized by the overproduction of mature blood cells, and the tendency to evolve into acute leukaemia. In solid tumours, calreticulin (CALR) overexpression on the cell surface, produ
Publikováno v:
Journal of Clinical Oncology. 36:7065-7065
7065Background: Myelodysplastic syndromes (MDS) are malignant disorders leading to acute leukaemia (AML). Recent breakthroughs identified down-regulation of PU.1 in high risk MDS and AML, with work...
Publikováno v:
Journal of Clinical Oncology. 35:e18558-e18558
e18558 Background: PU.1 is a key transcription factor in haematopoiesis that plays important roles in various haematological malignancies. Previously, significant down-regulation of PU.1 has been reported in high risk myelodysplastic syndrome (MDS) a